Previous Next

Dr. Singh

Dr. Singh, a doctor who practices in Bihar, one of India's poorest and most populous states, has been pleased with the impact of his Brilliance unit: “[Brilliance] serves my purpose. I’m quite happy with it.”

Dr. S Kumar

“Compared to other phototherapy, Brilliance is far more effective and user-friendly,” reports Dr. S. Kumar, a doctor in a government hospital in Tamil Nadu, India. Doctors around the world use the Bhutani Nomogram (pictured here), to assess a newborn’s risk for developing hyperbilirubinemia and determine appropriate treatment measures, including phototherapy.


Devi is a young mother whose baby girl was suffering severe jaundice. After three days under a CFL device at a government hospital in Tamil Nadu, India, her baby’s condition had not improved. The baby was then moved to a double-sided Brilliance device and within four days, her bilirubin levels were brought down to a normal range. Much to her mother’s relief, the baby was finally out of danger.

Baby Hope

Baby Hope was the first baby treated with Brilliance. He weighed less than 3 lbs. at birth and was so jaundiced that he required an exchange transfusion. Fearing that the baby would not survive the transfusion, his pediatrician decided to use Brilliance instead. After one night under Brilliance, Baby Hope's bilirubin levels dropped by a third, and he no longer required an exchange transfusion.

Dr. Jain

Many nurses and doctors have found that using Brilliance has decreased the time that babies need to spend in phototherapy. Dr. Jain, a doctor at a hospital in Uttar Pradesh, commented: “When I want quicker results… I use Brilliance LED and find it to be very successful.” Decreased treatment times means babies can be reunited and bonding with their mothers sooner.

Nurse Rebecca

Nurse Rebecca has worked in maternity wards for over 25 years, and is a big fan of Brilliance. She used Brilliance at the hospital she worked at previously, and when she was hired by her current employer in Chennai, India as one of a new hospital's founding nurses, she requested a Brilliance unit for the ward. “I like it,” she says. “Very easy to use.”

Kerala Public Hospital

This baby is being treated with one of three Brilliance units that a public hospital in Kerala, India purchased for its neonatal intensive care unit (NICU) that opened in August 2013.

South African Hospital

This Level 2 hospital, located in the Gauteng province in South Africa, serves a population of over 900,000 and handles about 400 deliveries per month. The doctors used a Brilliance unit for a month and saw treatment times go from 1-2 weeks with their existing fluorescent tube devices to 2-3 days with Brilliance. The hospital has since purchased 15 units for use in its NICU.

Dr. Choudhary

A physician in Bihar, Dr. Choudhary was so pleased with the Brilliance unit that he bought that he planned to buy a second unit once his clinic expanded: "This unit is very good. Results were excellent."


Over 6 million babies requiring treatment for severe jaundice each year are not receiving the treatment they need. When left untreated, severe jaundice can result in disability or death.

D-Rev’s intervention

By designing a low-cost, high-quality phototherapy device that can be delivered through an economically self-sustaining distribution model, D-Rev aims to increase access to effective phototherapy throughout the developing world, with the end goal of reducing the number of deaths and disabilities due to untreated severe jaundice.

Measuring impact

To measure our progress, we track three main indicators:

  • Number of babies treated with Brilliance units (“Babies Treated”)
  • Number of babies treated with Brilliance units who otherwise would not have received effective treatment (“Babies Otherwise”)
  • Number of deaths and disabilities averted through the use of Brilliance units (“D&D Averted”)

We calculate these numbers on a per-unit basis, using an algorithm based on machine data and assumptions drawn from fieldwork and academic research, and then sum the results to determine our total estimated impact. For a detailed description of the assumptions and calculations we use, check out our step-by-step explanation.

Quick Facts

Goal: Reduce the number of neonatal deaths and disabilities due to untreated severe jaundice

Project started: 2010
Product launched: 2012
CE Mark granted: 2013

Current status: Product is on the market. D-Rev is now scaling for broader market penetration and impact.

Product Manager: Daniel Wald